Latest Diabetic Nephropathy News
Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk
Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years.
Skin Autofluorescence Predicts T2DM, Heart Disease, Mortality
Prediction independent of traditional risk factors such as MetS, glucose, HbA1c in general population
Rotating Night Shift Work, Lifestyle Factors Linked to T2DM
Significant additive interaction identified for night shift work, unhealthy lifestyle for female nurses
Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk
Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
Insulin Needed for T2DM Tx Set to Increase >20 Percent by 2030
Using higher HbA1c target in over-75s could increase disability-adjusted life-years by 44.2%.
Switching to High-Deductible Insurance Delays Diabetes Care
Delays in seeking care for first major symptom of macrovascular disease, first major diagnostic test.
SGLT2 Inhibitors May Reduce CV, Renal Risks in Type 2 Diabetes
SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Higher Risk for Amputation, DKA With SGLT2 Inhibitors for T2DM
Risk increased for lower-limb amputation, diabetic ketoacidosis compared with GLP1 receptor agonists.
AHA: Lasting Benefit for CABG in Diabetes, Multivessel Disease
Lower all-cause mortality in CABG group vs PCI-DES group after median follow-up of 7.5 years.
Changes in Risk Indicators of MetS Severity Tied to T2DM Risk
For patients with prediabetes, changes in risk indicators during intervention tied to T2DM, CVD risk
AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
Treatment resulted in lower HF hospitalization rate in patients with, without atherosclerosis.
Bardoxolone Methyl Leads to Weight Loss in T2D With Concurrent Chronic Kidney Disease
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk
Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients
TRT May Reduce Mortality Without Improving CV Health in Diabetes
In a study, reduced mortality was found among TRT users with type 2 diabetes after adjustment for cardiovascular risk factors.
Canagliflozin Approved to Reduce Risk of Major Adverse Cardiovascular Events
The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.
Newsletter Signup
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Anemia
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetes
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Hemodialysis
- Hyperphosphatemia
- Hypertension
- Hyperuricemia
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
- Transplantation
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Nocturia, Overactive Bladder Improved With PTNS
- Many Americans Unaware of Promise of Personalized Medicine
- Noninferior CV Outcomes for Linagliptin in T2D With High CV, Renal Risk
- VDRAs Do Not Lower Cardiovascular Event Risk in HD